Table 1a:
Waitlisted Kidney Cohort Characteristics by Era
| Characteristic | Waitlist Era | Total (N=348,128) | P value | ||
|---|---|---|---|---|---|
| Era 1:2007 – 2010 (N=118,283) | Era 2: 2011 – 2014 (N=115,272) | Era 3: 2015–2018 (N=114,573) | |||
| Race | <0.0011 | ||||
| White | 54,722 (46.3%) | 50,996 (44.2%) | 49,864 (43.5%) | 155,582 (44.7%) | |
| Black or African American | 35,099 (29.7%) | 33,691 (29.2%) | 31,693 (27.7%) | 100,483 (28.9%) | |
| American Indian or Alaska Native | 1,161 (1.0%) | 1,270 (1.1%) | 1,114 (1.0%) | 3,545 (1.0%) | |
| Asian | 7,170 (6.1%) | 7,943 (6.9%) | 8,563 (7.5%) | 23,676 (6.8%) | |
| Native Hawaiian, Pacific Islander | 444 (0.4%) | 548 (0.5%) | 570 (0.5%) | 1,562 (0.4%) | |
| Hispanic / Latino | 19,300 (16.3%) | 20,324 (17.6%) | 21,868 (19.1%) | 61,492 (17.7%) | |
| Multi-Racial | 387 (0.3%) | 500 (0.4%) | 901 (0.8%) | 1,788 (0.5%) | |
| Sex | <0.0011 | ||||
| Female | 46,931 (39.7%) | 44,606 (38.7%) | 43,414 (37.9%) | 134,951 (38.8%) | |
| Male | 71,352 (60.3%) | 70,666 (61.3%) | 71,159 (62.1%) | 213,177 (61.2%) | |
| Age at listing | <0.0012 | ||||
| Mean (SD) | 51.4 (13.1) | 52.2 (13.0) | 52.6 (13.1) | 52.0 (13.1) | |
| Median | 53.0 | 54.0 | 55.0 | 54.0 | |
| Q1, Q3 | 43.0, 61.0 | 44.0, 62.0 | 44.0, 63.0 | 43.0, 62.0 | |
| Range | (18.0–90.0) | (18.0–88.0) | (18.0–89.0) | (18.0–90.0) | |
| BMI at listing (kg/m2) | <0.0012 | ||||
| Missing | 1,979 (1.7%) | 311 (0.3%) | 433 (0.4%) | 2,723 (0.8%) | |
| Mean (SD) | 28.4 (5.7) | 28.9 (5.7) | 29.0 (5.5) | 28.8 (5.7) | |
| Median | 28.0 | 28.0 | 29.0 | 28.0 | |
| Q1, Q3 | 24.0, 32.0 | 25.0, 33.0 | 25.0, 33.0 | 25.0, 33.0 | |
| Range | (15.0–60.0) | (15.0–59.0) | (15.0–60.0) | (15.0–60.0) | |
| BMI at listing (kg/m2) | <0.0011 | ||||
| Missing | 1,983 (1.7%) | 311 (0.3%) | 437 (0.4%) | 2,731 (0.8%) | |
| [15–19) | 2,143 (1.8%) | 1,820 (1.6%) | 1,596 (1.4%) | 5,559 (1.6%) | |
| [19–25) | 29,025 (25.0%) | 25,715 (22.4%) | 24,405 (21.4%) | 79,145 (22.9%) | |
| [25–30) | 38,867 (33.4%) | 37,484 (32.6%) | 37,503 (32.9%) | 113,854 (33.0%) | |
| [30–40) | 42,201 (36.3%) | 45,735 (39.8%) | 47,330 (41.5%) | 135,266 (39.2%) | |
| [40–60) | 4,064 (3.5%) | 4,207 (3.7%) | 3,302 (2.9%) | 11,573 (3.4%) | |
| Dialysis Status at listing | <0.0011 | ||||
| No | 29,649 (25.1%) | 26,691 (23.2%) | 34,600 (30.2%) | 90,940 (26.1%) | |
| Yes | 88,634 (74.9%) | 88,581 (76.8%) | 79,973 (69.8%) | 257,188 (73.9%) | |
| Total Serum Albumin | <0.0012 | ||||
| Missing | 14,318 (12.1%) | 6,334 (5.5%) | 3,096 (2.7%) | 23,748 (6.8%) | |
| Mean (SD) | 3.8 (0.6) | 3.9 (0.6) | 3.9 (0.6) | 3.9 (0.6) | |
| Median | 3.9 | 3.9 | 4.0 | 3.9 | |
| Q1, Q3 | 3.5, 4.2 | 3.5, 4.3 | 3.6, 4.3 | 3.5, 4.3 | |
| Range | (0.5–9.9) | (0.5–9.8) | (0.5–9.8) | (0.5–9.9) | |
| Diabetes Status | <0.0011 | ||||
| Missing | 1,264 (1.1%) | 190 (0.2%) | 15 (0.0%) | 1,469 (0.4%) | |
| No | 68,336 (58.4%) | 63,426 (55.1%) | 62,984 (55.0%) | 194,746 (56.2%) | |
| Yes | 48,683 (41.6%) | 51,656 (44.9%) | 51,574 (45.0%) | 151,913 (43.8%) | |
| Hypertension | <0.0011 | ||||
| Missing | 28,150 (23.8%) | 19,171 (16.6%) | 109,896 (95.9%) | 157,217 (45.2%) | |
| No | 10,388 (11.5%) | 10,378 (10.8%) | 582 (12.4%) | 21,348 (11.2%) | |
| Yes | 79,745 (88.5%) | 85,723 (89.2%) | 4,095 (87.6%) | 169,563 (88.8%) | |
| States by Expansion Year | <0.0011 | ||||
| Missing | 162 (0.1%) | 177 (0.2%) | 263 (0.2%) | 602 (0.2%) | |
| Initial expansion | 61,966 (52.5%) | 59,916 (52.1%) | 59,289 (51.9%) | 181,171 (52.1%) | |
| Late expansion | 14,622 (12.4%) | 13,651 (11.9%) | 13,057 (11.4%) | 41,330 (11.9%) | |
| Later/No expansion | 41,533 (35.2%) | 41,528 (36.1%) | 41,964 (36.7%) | 125,025 (36.0%) | |
1
Chi-Squared
2
ANOVA F-Test